Level Bio (LEVBIO) Q2 2025 earnings summary

Executive summary

• Revenue grew 46% year-over-year in Q2 2025 and 44% for the first half, reflecting strong sales momentum and successful strategic initiatives.

• Gross margin improved to 52% in Q2, with a 7% sequential sales increase from Q1.

• Net loss after tax narrowed to -1,447 KSEK in Q2 and -2,283 KSEK for H1, showing significant improvement over prior periods.

• Subsidiaries secured key orders and certifications, strengthening market position and operational credibility.

• Platform enhancements and new business initiatives, including a Q4 pilot and lab partnerships, are underway.

Financial highlights

• Q2 net revenue: 8,381 KSEK (up 46% YoY); H1 net revenue: 16,188 KSEK (up 44% YoY).

• Q2 gross margin: 52% (vs. 51% prior year); H1 gross margin: 51% (vs. 52%).

• Q2 operating loss: -1,498 KSEK (improved from -3,195 KSEK YoY); H1 operating loss: -2,392 KSEK (improved from -5,720 KSEK).

• Cash flow positive in Q2 (213 KSEK) and H1 (480 KSEK), reversing negative flows from prior year.

• Cash and equivalents at period end: 1,558 KSEK.

Segment performance

• Techtum Lab secured a 1 MSEK order and achieved ISO 9001:2015 certification, enhancing its market standing.

• CyberGene received its first commercial order in South Africa, signaling international traction.

• Manufacturing for prenatal diagnostics and male infertility products is recovering, with recurring revenue streams stabilizing.

• New design concern platform with multiple logins and operative items, indicating ongoing development.

• Activity logs and custom features have been added, focusing on cost efficiency.